CD44 and breast carcinoma: Currently, BCSCs are usually identified by expression of specific phenotypes; CD44+/CD24−/low and/or CD133+ are most frequently used (Li et al., 2017), and it is identified as a small subpopulation of heterogeneous breast cancer cells with strong self-renewal and proliferation properties (Zhang et al., 2020).